Prise en charge pratique des patients sous ustékinumab
Février 2017
1. Gottlieb A, Menter A, Mendelsohn A et al. Ustekinumab, a human interleukin 12/23 monoclonal
antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.
Lancet 2009;373:633-40. Erratum in: Lancet 2009;373:1340. Lancet 2010;376:1542.
2. McInnes IB, Kavanaugh A, Gottlieb AB et al. Efficacy and safety of ustekinumab in patients
with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, place-
bo-controlled PSUMMIT 1 trial. Lancet 2013;382:780-9.
3. Ritchlin C, Rahman P, Kavanaugh A et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal
antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biolo-
gical and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase
3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis
2014;73:990-9.
4. Kavanaugh A, Ritchlin C, Rahman P et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal anti-
body, inhibits radiographic progression in patients with active psoriatic arthritis: results of an
integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-
blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis 2014;73:1000-6.
5. Kavanaugh A, Puig L, Gottlieb AB et al. Efficacy and safety of ustekinumab in psoriatic arthritis
patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two
phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2). Ann
Rheum Dis 2016 Apr 20. [Epub ahead of print]
6. Gossec L, Smolen JS, Ramiro S et al. European League Against Rheumatism (EULAR) recom-
mendations for the management of psoriatic arthritis with pharmacological therapies: 2015
update. Ann Rheum Dis 2016;75:499-510.
7. Coates LC, Kavanaugh A, Mease PJ. Group for Research and Assessment of Psoriasis and
Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol
2016;68:1060-71.
8. Dougados M, Combe B, Braun J et al. A randomised, multicentre, double-blind, placebo-controlled
trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial.
Ann Rheum Dis 2010;69:1430-5.
9. Poddubnyy D, Hermann KG, Callhoff J et al. Ustekinumab for the treatment of patients with ac-
tive ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study
(TOPAS). Ann Rheum Dis 2014;73:817-23.
10. Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha)
Naive Participants With Active Radiographic Axial Spondyloarthritis - Full Text View -Clinical-
Trials.gov [Internet]. [cited 2016 May 16]. Available from:https://clinicaltrials.gov/ct2/show/
NCT02437162
11. A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha)
Refractory Participants With Active Radiographic Axial Spondyloarthritis - Full Text View -Clinical-
Trials.gov [Internet]. [cited 2016 May 16]. Available from:https://clinicaltrials.gov/ct2/show/
NCT02438787
12. An Efficacy and Safety Study of Ustekinumab in Participants With Active Nonradiographic Axial
Spondyloarthritis - Full Text View - ClinicalTrials.gov [Internet]. [cited 2016 May 16]. Available
from: https://clinicaltrials.gov/ct2/show/NCT02407223
13. Sandborn WJ, Feagan BG, Fedorak RN et al. A randomized trial of Ustekinumab, a human
interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease.
Gastroenterology 2008;135:1130-41.
Références